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Abstract:  Background: Several recent meta-analyses of adverse event data from randomized controlled trials with 
rosiglitazone reveal a possible association between this thiazolidinedione and an increased risk of ischemic myocardial 
events. This has led to debate on the overall clinical benefit of glitazone therapy for type 2 diabetes. Pioglitazone, on the 
other hand, has the most extensive cardiovascular outcomes database of all current glucose-lowering therapies, including a 
large prospective randomized controlled trial designed specifically to assess cardiovascular outcomes (PROactive). The 
available data suggest that pioglitazone is associated with a reduction in macrovascular risk. 
Aims: In this review, we highlight some of the key factors that need to be considered when assessing the net clinical 
benefit of thiazolidinediones, focussing on both class effects and those specific to either rosiglitazone or pioglitazone.  
Results: For pioglitazone there appears to be no increase in the risk of overall macrovascular events and no adverse 
clinical consequences of developing signs of heart failure. Furthermore, there is good evidence of significant benefit 
regarding the composite of death, MI or stroke.  
Conclusion: The benefits seen with pioglitazone appear to outweigh the risks. 
INTRODUCTION — CONFUSION REIGNS IN THE 
WORLD OF TZDS 
  Clinicians have a wide range of different glucose-
lowering drug options to call upon when selecting the most 
appropriate treatment for their patients with type 2 diabetes. 
In recent years, the two widely marketed thiazolidinediones 
(TZDs) — pioglitazone and rosiglitazone — have become a 
well-established component of treatment algorithms for the 
metabolic management of type 2 diabetes [1-3]. Both agents 
offer robust improvements in glycemic control that are at 
least comparable to those seen with established agents, such 
as metformin and the sulfonylureas [4-6]. More importantly, 
this effect appears to be remarkably durable with the TZDs, 
which may relate to their potential ß-cell preserving 
properties [7]. This is a particularly desirable property in a 
glucose-lowering agent, as it is the progressive failure and 
loss of ß-cells that is ultimately responsible for the onset and 
progression of type 2 diabetes [8]. When considering 
whether to use a TZD, clinicians also need to consider the 
potential impact of several other well-established charac-
teristics of these agents, including their propensity to cause 
edema (and subsequently signs and/or symptoms of heart 
failure) and weight gain [9-13].  
  However, recent studies and analyses have added another 
characteristic of TZDs into the equation — their potential 
impact on cardiovascular (CV) events. Patients with type 2 
diabetes are already at increased risk for heart failure and 
other adverse CV events and it would be cause for concern if  
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this risk was increased further by glucose-lowering therapy. 
Several meta-analyses have suggested that there may be a 
signal for increased risk of myocardial ischemic events with 
rosiglitazone therapy, which has ignited debate and instilled 
uncertainty regarding the place of TZDs in diabetes 
treatment strategies [14,15]. Furthermore, these results 
appear to contrast with those for pioglitazone based on meta-
analyses showing a reduction in CV events, as well as the 
results of the PROactive (PROspective pioglitAzone Clinical 
Trial In macroVascular Events) study, which provide the 
only robust CV outcomes data for a TZD to date [16,17].  
  The confusion is compounded further by uncertainty over 
the exact nature of the heart failure reported with both TZDs 
and whether it has any adverse consequences. Myocardial 
ischemic events are a consequence of reduced blood flow to 
the cardiac muscle. However, there is no evidence in the 
literature to suggest that the TZDs exert any direct adverse 
effect on cardiac function. Rather, the heart failure asso-
ciated with TZD therapy may be associated with their 
established effects on fluid retention and, as such, may be 
manageable and/or reversible (for review see [18]).  
  The debate sparked by the reports of increased 
myocardial ischemic events with rosiglitazone has led to a 
diverse range of individual ideas on the best course of action 
for patients on a TZD (especially rosiglitazone), including: 
no action; increased monitoring; switching to a non-TZD 
glucose-lowering drug; or switching from rosiglitazone to 
pioglitazone [19]. In this review, we consider the available 
evidence that allows an overall assessment of any potential 
(or genuine) CV clinical benefits or deficits of TZD therapy 
and ask whether the concern is justified for either 
rosiglitazone or pioglitazone. In particular, we consider both 
the class effects and drug-specific effects of the TZDs. 156 Current Cardiology Reviews, 2009, Vol. 5, No. 3 Erdmann et al. 
SHOULD WE EXPECT GLUCOSE-LOWERING 
DRUGS TO IMPACT ON CV OUTCOMES IN TYPE 2 
DIABETES? 
  All current glucose-lowering agents, including the TZDs, 
were approved primarily on their ability to improve glycemic 
control with acceptable tolerability over relatively short-
periods, a process that has at times received criticism (e.g. 
[20,21]). Unfortunately, this process does not allow the 
adequate assessment — prior to approval — of either long-
term safety or benefit regarding relevant clinical outcomes, 
such as CV events.  
  Whilst the need to reduce acute hyperglycemic crises and 
their serious consequences is readily apparent (and usually 
requires insulin therapy), it is the insidious long-term 
consequences of more moderate hyperglycemia and other 
metabolic disturbances that are most relevant to the patient 
with type 2 diabetes. Ultimately, it is the impact of diabetes 
on micro- and macrovascular disease that is responsible for 
much of the morbidity and mortality associated with the 
disease [22]). 
  Based on the limited clinical trial evidence available, it is 
assumed that reducing hyperglycemia over the long term, 
through whatever means, reduces the long-term risk of the 
microvascular and (probably) macrovascular complications 
associated with type 2 diabetes [23-26]. Unfortunately, the 
intensive blood glucose sub-study (target HbA1c <6.0%) in 
the ACCORD (Action to Control CardiOvascular Risk in 
Diabetes) study of patients with type 2 diabetes and vascular 
disease/multiple CV risk factors has been stopped due to 
safety concerns (an increased mortality rate relative to the 
standard regimen, with an HbA1c <7.0%), but data from the 
standard treatment arm will still provide invaluable insight 
into CV risk reduction. Most glucose-lowering drugs, 
including the TZDs, have multiple and differing effects on 
diverse biological processes (some of which may be 
potentially beneficial, others potentially detrimental) that 
may determine the effect on any particular clinical end point 
(e.g. cardiovascular disease [CVD]). Thus, while it is likely 
that lowering glucose is associated with reductions in 
vascular events, we cannot accurately predict the effect 
(good or bad) of any individual drug on CV (or any other) 
outcomes without suitable outcomes data. Unfortunately, 
adequate outcomes data are still lacking for the majority of 
glucose-lowering agents, in spite of some potential safety 
issues (Table 1).  
SHOULD WE EXPECT TZDS TO IMPACT ON CV 
OUTCOMES IN TYPE 2 DIABETES? 
  TZDs are agonists for nuclear peroxisome proliferator 
activated receptors (PPAR) and exert their glucose-lowering 
effect by binding to PPAR. Metabolically, TZDs act as 
Table 1. Known or Potential Cardiovascular Issues with the Major Classes of Oral Glucose-Lowering Agents 
Oral Agent Class  Known or Potential Cardiovascular Issues 
Sulfonylureas 
(Glyburide, Glipizide, 
Glimepiride, Others) 
• Hypoglycemia may precipitate ischemia, arrhythmia [27] 
• Cardiac KATP channel closure may impair ischemic preconditioning (this may be more important with 
specific agents, notably glyburide) [27,28] 
• Long-term outcomes trials suggest no harmful CV effects when used as part of an intensive glucose 
control strategy (based on the UKPDS and ADVANCE) [23,29] 
• Potential harmful effect on outcomes when used in combination with metformin (based on the UKPDS 
and a meta-analysis of observational studies) [24,30] 
Glinides 
(Nateglinide, Repaglinide) 
• Hypoglycemia may precipitate ischemia, arrhythmia [27] 
• Cardiac KATP channel closure may impair ischemic preconditioning (this may be more important with 
repaglinide) [27,31] 
• No long-term data regarding CV safety and efficacy (data for nateglinide in prediabetes will be available 
soon from NAVIGATOR) [32] 
Biguanides 
(Metformin) 
• May improve CVD outcomes in overweight patients when used as the basis of an intensive glucose 
control strategy (based on a relatively small study embedded in the UKPDS) [24] 
• Should not be used in acute or unstable HF because of lactic acidosis risk [27,33] 
• Potential harmful effect on outcomes when used in combination with sulfonylureas (based on the UKPDS
and a meta-analysis of observational studies) [24,30] 
-glucosidase inhibitors 
(Acarbose, Miglitol) 
• Improves postprandial glucose excursions, which are more tightly associated with CVD than fasting 
glucose [27,34] 
• May reduce MI risk in prediabetes (based on a small number of events in STOP-NIDDM) or type 2 
diabetes (meta-analysis of RCTs) [27,34] 
Thiazolidinediones 
(Rosiglitazone, Pioglitazone) 
• May precipitate clinical HF in predisposed individuals [27] 
• Pioglitazone may reduce MI, stroke risk (based on PROactive and meta-analyses of RCTs) [27] 
• Rosiglitazone may increase MI risk (based on meta-analyses of RCTs) [27] 
DPP-4 inhibitors 
(Sitagliptin, Vildagliptin) 
• No long-term data regarding CV safety and efficacy [27] 
• Effects on CV risk entirely unknown [27] 
Table adapted from ref. [27] 
ADVANCE=Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation 
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insulin sensitizers to improve glucose uptake, lower blood 
glucose and reduce hyperinsulinemia. Both pioglitazone and 
rosiglitazone have multiple effects on metabolic parameters 
that could potentially have an impact on CV outcomes 
(Table  2), although there are some important differences 
between the two drugs.  
  Certainly, both TZDs have been shown to produce 
clinically meaningful reductions in HbA1c, alongside low 
rates of hypoglycemia as either mono- or combination 
therapy and, therefore, provide a useful option when 
pursuing recommended glycemic goals [4,35]. Glycemic 
control with TZDs also appears to be particularly durable, as 
demonstrated in ADOPT (A Diabetes Outcome Prevention 
Study), where rosiglitazone was associated with significantly 
lower rates of monotherapy failure compared with either 
metformin or glyburide [7]. In addition to their ability to 
lower glucose, both drugs also have a small beneficial effect 
on blood pressure [36,37]. However, while both drugs 
modify the lipid profile in patients with type 2 diabetes, there 
are notable distinctions. As shown in a head-to-head 
comparison, rosiglitazone increases low-density lipoprotein 
cholesterol (LDL-C) concentration, increases the number of 
atherogenic (i.e. apo B100-containing) particles and tends to 
raise triglycerides, whereas pioglitazone is neutral with 
respect to LDL-C levels (but does change favorably the size 
and concentration of LDL particles), tends to lower apo 
B100 and reduces plasma triglyceride levels [38,39]. 
Additionally, pioglitazone is more effective at raising high-
density lipoprotein cholesterol (HDL-C) and converting 
small, dense LDL particles to larger, more buoyant ones 
[38,39]. Accordingly, significant improvements in 
triglycerides, total cholesterol and HDL-C have been 
reported when patients are switched from rosiglitazone to 
pioglitazone, while glycemic control remains stable [40].  
  In addition to their impact on well-established risk 
factors, both TZDs also have potentially beneficial effects on 
a myriad of non-traditional risk markers associated with 
vascular function and CVD (for reviews, see [41-43]). 
Among these, TZDs improve markers of inflammation (e.g. 
C-reactive protein [CRP]), influence components of the 
coagulation cascade (e.g. plasminogen activator inhibitor-1 
[PAI-1]) and increase levels of the anti-atherosclerotic 
adipokine, adiponectin [44-47]. They also modulate 
processes involved in macrophage foam cell formation, 
plaque stability and the response to vascular injury, as well 
as improving endothelial function and microalbuminuria 
[43,48]. Studies in animal models also demonstrate their 
ability to improve outcomes after experimentally induced 
myocardial infarction (MI) or stroke [49-52]. In human 
studies, they also improve cardiac performance and 
pioglitazone has been shown to reduce the progression of 
carotid intima-media thickness (CIMT), which is a well-
established surrogate for atherosclerosis [53,54]. Most 
recently, pioglitazone was shown to reduce the progression 
of atherosclerosis, as measured using intravascular 
ultrasound, and improve CV risk factors over 18 months, 
whereas there was a progression of coronary atherosclerosis 
with glimepiride [55]. 
  Differential gene expression between TZDs, based on the 
selective PPAR modulator (SPPARM) model of PPAR
ligand action, may provide a mechanistic explanation for 
some of the differences within this class of drugs [56,57]. 
According to this model, the ligand-receptor (i.e. TZD-
PPAR) complex for each TZD takes on a different 
Table 2.  Key Factors to Consider when Determining the Net Clinical Benefit of either Pioglitazone or Rosiglitazone  
Pioglitazone 
Beneficial/Potentially Beneficial Factors  Detrimental/Potentially Detrimental Factors 
• Reduced risk of all-cause mortality, MI and stroke (based on 
PROactive and meta-analyses) and no evidence of increased risk 
• Reduced risk of recurrent MI  
• Reduced risk of recurrent stroke 
• Reduction in restenosis/repeat TVR (relevant only in patients 
undergoing PCI) 
• Effects on traditional metabolic risk factors (glucose, triglycerides, 
HDL-C, blood pressure, LDL particle concentration) 
• Effects on surrogate endpoints (CIMT, IVUS) 
• Effects on non-traditional risk markers 
• Increase in edema and weight gain 
• Increase in signs of heart failure (which is not associated with adverse 
CV outcomes) 
• Possible increase in peripheral revascularization in patients with 
evidence of occlusive PAD 
• Possible increase in distal fractures (postmenopausal women) 
Rosiglitazone 
Beneficial/Potentially Beneficial Factors  Detrimental/Potentially Detrimental Factors 
• Reduction in restenosis/repeat TVR (relevant only in patients 
undergoing PCI) 
• Effects on traditional metabolic risk factors (glucose, HDL-C, blood 
pressure) 
• Effects on surrogate endpoints (CIMT) 
• Effects on non-traditional risk markers 
• Signal for increased cardiac ischemic events (based on meta-analyses)  
• Increase in edema and weight gain  
• Increase in signs of heart failure  
• Possible increase in distal fractures (postmenopausal women) 
• Metabolic effects (increased LDL concentration and particle number) 
CIMT=carotid intima-media thickness; PCI=percutaneous coronary intervention; IVUS=intravascular sonography; TVR=target vessel revascularization158 Current Cardiology Reviews, 2009, Vol. 5, No. 3 Erdmann et al. 
conformation, resulting in distinct patterns of interactions 
with nuclear cofactors, histones and other transcription 
factors, etc. and, consequently, leading to different patterns 
of gene expression for each individual TZD [57,58]. For 
instance, a recent study showed complex, only partially-
overlapping gene expression profiles for over 300 genes 
regulated by troglitazone, rosiglitazone and pioglitazone 
(Fig.  1) and among the common genes, time course and, 
dose-response studies also revealed further differentiation in 
terms of TZD-specific expression kinetics [57]. Furthermore, 
recruitment among the myriad of nuclear receptor coacti-
vators, co-repressors and coregulators — protein moieties 
that appear to play a critical role in transcriptional regulation 
influencing a wide variety of biological processes — 
presents a whole new level of complexity that may depend 
on their tissue specificity, and their interactions with each 
other and with other signalling pathways [58-61]. As such, 
TZD-specific interactions with these nuclear cofactors may 
be relevant to differential effects of individual TZDs in 
different tissues and under different metabolic conditions. 
Several PPAR-independent off-target effects that may 
contribute to the CV risk-benefit profile of individual TZDs 
have also been reported [62,63]. 
  Thus, based on their multiple effects on glycemia, lipid 
profiles, blood pressure, biomarkers and surrogate CV 
endpoints, we would anticipate that TZDs have the potential 
to influence CV outcomes positively. At the same time, it 
would not be surprising if individual TZDs differed in the 
nature and/or extent of that impact, given their differing 
effects on gene expression and lipids. As noted above, rosig-
litazone (but not pioglitazone) may have some potentially 
detrimental absolute effects on lipids (notably, increased 
LDL-C concentration and apoB100-containing particle 
number), and any potentially beneficial effects of rosiglita-
zone on lipids (e.g., increased HDL-C concentration and 
increased LDL particle size) appear to be more marked with 
pioglitazone, which also has the additional benefits of 
lowering triglycerides and apoB100-containing particle 
number. The greater effect of pioglitazone on HDL-C may 
be particularly relevant, as it appears to be a key factor 
underlying the significant slowing of CIMT progression seen 
with this TZD in patients with type 2 diabetes [64].
WHAT ARE THE OBSERVED EFFECTS OF TZDS 
ON ACTUAL CLINICAL OUTCOMES? 
Macrovascular Events 
Pioglitazone 
  The most robust data on CV outcomes with TZDs comes 
from the PROactive trial, which involved over 5000 patients 
with type 2 diabetes and established macrovascular disease 
[16,65-69]. This prospective, randomized, placebo-cont-
rolled study showed that, over approximately 3 years, piogli-
tazone therapy was associated with a statistical trend towards 
benefit (hazard ratio [HR]=0.90, 95% confidence interval 
[CI] [0.80, 1.02], p=0.095) for the primary composite 
macrovascular end point (a complex composite of cerebral, 
cardiac and peripheral events and both disease-related and 
procedural end points). A statistically significant reduction in 
the main secondary endpoint of the composite of all-cause 
mortality, MI or stroke (HR=0.84, 95% CI [0.72, 0.98], 
p=0.027) was also reported (Fig. 2), along with significant 
effects on several other major adverse cardiovascular events 
(MACE) end points [16,68].  
  These results are supported by a recent meta-analysis of 
19 randomized controlled trials (RCTs) involving pioglita-
Fig. (1). Different thiazolidinediones have only partially overlapping gene expression profiles 
The total number of genes regulated by a particular TZD is shown next to its name. The number of genes uniquely regulated by a particular 
TZD is contained in the non-overlapping regions of each circle. The numbers of genes similarly regulated by two or three TZDs are
contained in the overlapping regions of the circles [57]. (Reprinted from Biochem Biophys Res Commun, 364(3), Sears DD, Hsiao A,
Ofrecio JM, Chapman J, He W, Olefsky JM, Selective modulation of promoter recruitment and transcriptional activity of PPARgamma, 515-
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zone, which showed a significant decrease in the composite 
of death, MI or stroke (HR=0.82, 95% CI [0.72, 0.94], 
p=0.005) and a non-significant decrease in the risk of MI 
(HR=0.81, 95% CI [0.64, 1.02], p=0.08) relative to 
comparator therapies (Fig. 2), and these results held when 
PROactive was omitted from the analyses [17]. Also notable 
in PROactive were statistically significant reductions in the 
risk of recurrent MI (HR=0.72, 95% CI [0.52, 0.99], 
p=0.045) or recurrent stroke (HR=0.53, 95% CI [0.34, 0.85], 
p=0.009) [65,66]. In addition, pioglitazone also appeared to 
be particularly effective at reducing macrovascular events in 
patients with chronic kidney disease, but was relatively 
ineffective in patients with peripheral arterial disease (PAD) 
at baseline [67,69]. There was, however, an excess of leg 
revascularizations in patients treated with pioglitazone — 
this was restricted to those patients with evidence of PAD at 
baseline (N=1274), and most of the excess events occurred 
in the first year of the study when a total of 42 leg 
revascularization events occurred in the pioglitazone arm 
versus 24 events in the placebo arm, compared with 39 and 
41 events, respectively, during the second and third years of 
the study [69]. 
Rosiglitazone 
  In contrast to the findings with pioglitazone, several 
separate meta-analyses of RCTs involving rosiglitazone have 
raised the possibility of an increased risk of MI and/or 
Fig. (2). Pioglitazone decreases the risk of major macrovascular events
Data are for the composite of all-cause mortality, MI and stroke from (A) PROactive and (Reprinted from The Lancet, 366, Dormandy JA, 
Charbonnel B, Eckland DJ; PROactive investigators, Secondary prevention of macrovascular events in patients with type 2 diabetes in the 
PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial, 1279–1289, Copyright 
© 2005, with permission from Elsevier). (B) a meta-analysis of 19 randomized controlled trials [16,17]. (Reprinted with permission from 
Lincoff AM et al, JAMA 2007; 298: 1180–1188, Copyright © 2007 American Medical Association. All rights reserved). 160 Current Cardiology Reviews, 2009, Vol. 5, No. 3 Erdmann et al. 
ischemic cardiac events versus comparators, although it 
should be emphasised that none of the included studies were 
designed specifically to assess CV events and the studies 
have used different measures for relative risk (some have 
used HR, some have used the odds ratio [OR] and some 
relative risk [RR]) (Fig. 3) [14,15,70,71]. While the methods 
used to perform these meta-analyses have been the subject of 
considerable debate and consequently re-analysed using 
different criteria (e.g. [72]), they all showed a trend towards 
increased risk.  
  Using CV adverse event summary data from 42 studies 
(N=27,847) identified in the literature and other sources, 
Nissen and Wolski found that rosiglitazone was associated 
with a significant 43% increase in the risk of MI versus all 
comparators (OR=1.43, 95% CI [1.03, 1.98], p=0.03) and a 
64% non-significant increase in CV death (OR=1.64, 95% 
CI [0.98, 2.74], p=0.06) [14]. However, this apparent 
increased risk of CV death has not been reported in other 
meta-analyses of rosiglitazone outcomes and, when these 
data were analysed using various different (arguably more 
appropriate) statistical corrections, the increase in MI did not 
achieve statistical significance [72]. Two separate 
independent unpublished meta-analyses (performed by 
GlaxoSmithKline and the US Food and Drug Administration 
[FDA]) of patient-level data from a different dataset of 42 
studies both showed a significant increase in myocardial 
ischemic events with rosiglitazone (Fig. 3) [15,70]. A 
subsequent analysis of MI alone from this dataset, however, 
showed an increased risk that failed to reach significance 
(OR=1.59, 95% CI [0.93, 2.71]) [73]. A significant increase 
in MI with rosiglitazone was also reported in another 
separate meta-analysis that was restricted to the four long-
term (12 months) studies only (RR=1.42, 95% CI [1.06, 
1.91], p=0.02) [55]. Despite this, an increase in the incidence 
of MACE end points has not been consistently reported in 
meta-analyses of rosiglitazone outcomes.  
  These meta-analyses currently represent the best CV 
safety data available for rosiglitazone. Interim results from 
the ongoing RECORD (Rosiglitazone Evaluated for Cardiac 
Outcomes and Regulation of Glycaemia in Diabetes) trial — 
a prospective, randomized, open-label, uncontrolled non-
inferiority CV outcomes study with rosiglitazone — have 
been inconclusive, and it is difficult to make any conclusions 
from this early underpowered analysis [74]. RECORD was 
designed as a non-inferiority study comparing rosiglitazone 
Fig. (3). Available safety data for rosiglitazone and pioglitazone in terms of macrovascular risk relative to comparators 
Data are from meta-analyses, the interim results of the RECORD trial and the PROactive trial. The primary endpoint in RECORD was the 
composite of hospitalization or death due to CV causes. The primary endpoint in PROactive was the composite of all-cause mortality, MI 
(incl. silent MI), stroke, ACS, coronary revascularization, major leg amputation and leg revascularization. 
The dotted line represents the non-inferiority limit (1.2) for the upper CI in the RECORD study 
FDA=(US) Food and Drug Administration; GSK=GlaxoSmithKine; IHD=ischemic heart disease; OR=odds ratio; HR=hazard ratio; 
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(plus metformin or a sulfonylurea) with metformin and a 
sulfonylurea. Success was defined as the upper bound of the 
95% CI being less than 1.2 (a >20% increased risk in the 
primary end point of a composite of hospitalization or death 
from CV causes, including heart failure) with rosiglitazone. 
After 3.75 years, the risk of reaching the primary end point 
in the rosiglitazone group was not significantly different 
from the comparator group (HR=1.08, 95% CI [0.89, 1.31, 
p=0.43). However, the upper CI exceeded the predefined 
non-inferiority limit of 1.2 (Fig. 3). Similarly, there was no 
significant difference with regards to the important 
secondary composite end point of CV death, MI and stroke 
or the secondary end point of MI alone (HR=1.16, 95% CI 
[0.75, 1.81]), p=0.50 (Fig. 3). The risk of MI alone increased 
when events pending adjudication were included in the 
analysis (HR= 1.23, 95% CI [0.81, 1.86], p=0.34). It remains 
to be seen whether RECORD will ever have enough power 
to provide an authoritative answer regarding the ischemic 
myocardial danger signal noted in the rosiglitazone meta-
analyses, as it has had a much lower than expected event rate 
and a much higher than expected drop-out rate.  
Observational and Cohort Data 
  Observational studies represent another source of data 
that can be considered alongside RCTs and meta-analyses, 
but they should only be used for signal detection as they can 
only demonstrate an association and are subject to 
uncontrollable confounding and bias. A negative 
observational study does not mean a signal does not exist, 
merely that it has not been seen. In a recent retrospective 
cohort study from Canada, current TZD monotherapy was 
associated with a significantly increased risk of hospitali-
zation/admission for MI compared with other oral agent 
therapy [75]. When the data for individual TZDs were 
examined, the significant association persisted for 
rosiglitazone (RR=1.76, 95% CI [1.27, 2.44], p<0.001). 
Although there was no comparable increase in risk with 
pioglitazone, the analysis was limited by the smaller number 
of patients receiving that agent. Another study found a 
significant difference in the risk of MI and coronary 
revascularization between sulfonylureas (higher risk) and 
metformin (lower) risk, but no significant difference when 
either agent was compared with rosiglitazone, which 
appeared to impart a level of risk somewhere between the 
two [76]. A retrospective cohort study comparing 
rosiglitazone and pioglitazone appears to support the results 
of the meta-analyses [77]. The risk of hospitalization for MI 
was significantly lower for pioglitazone compared with 
rosiglitazone (HR=0.78, 95% CI [0.63, 0.96]), as was the 
risk of the composite of MI and coronary revascularization 
(HR=0.85, 95% CI [0.75, 0.98]). However, other 
observational studies have found no increased risk with 
rosiglitazone relative to other oral glucose-lowering agents 
(the OR for the risk of MI, CV death or stroke was found to 
be 1.2, p=040 for rosiglitazone versus comparators in the 
Rosen FDA analysis of 42 trials) [15]. 
Edema, Weight Gain and Signs of Heart Failure 
  Data from several sources (PROactive and RECORD, 
non-CV outcome RCTs, meta-analyses and observational 
studies) have established that both rosiglitazone and 
pioglitazone are associated with edema, weight gain and 
signs of heart failure [10-13,18,78]. Weight gain with 
pioglitazone appears to be associated primarily with fluid 
retention and there is currently no available evidence to 
suggest that this sort of weight gain is associated with any 
adverse macrovascular outcomes [79]. Importantly, however, 
heart failure that develops while on TZD therapy appears to 
be the result of sodium-water retention rather than any 
adverse effect on the myocardium (for review see [18]). In 
fact, some evidence suggests that TZDs may actually 
improve cardiac function (for review see [18]). These 
characteristics of TZD-induced heart failure were evident in 
analyses from PROactive. Although the risk of serious heart 
failure was clearly greater with pioglitazone, absolute 
macrovascular event rates were similar to placebo [79]. In 
fact, a time-to-event analysis among those patients deve-
loping signs of serious heart failure while on pioglitazone 
suggested a proportional decrease in event rates and 
mortality compared with those on placebo. The potential 
impact of heart failure associated with rosiglitazone therapy 
on CV outcomes has not been assessed. 
HOW CAN WE DECIDE WHICH PATIENTS WILL 
BENEFIT MOST (OR LEAST) FROM TZD 
THERAPY? 
  Unfortunately, there is relatively little robust evidence 
available to help to predict which patients might be at 
increased cardiac ischemic risk with rosiglitazone. Data from 
the various meta-analyses suggest that the risk may be higher 
in those on nitrates or concomitant insulin therapy or those 
with previous established CVD [15,70]. The US prescribing 
information for rosiglitazone recommends against combi-
nation with nitrates or insulin.  
  There is good evidence from PROactive to suggest which 
patients might benefit most or least from secondary 
prevention therapy with pioglitazone. Firstly, patients with a 
history of MI or stroke derived particularly marked 
reductions in the risk of recurrent events [65,66]. Secondly, 
the presence of renal dysfunction does not appear to be a 
limiting factor and patients with chronic kidney disease may 
in fact derive greater macrovascular benefit [67]. Patients 
with evidence of pre-existing occlusive PAD, however, 
would appear not to be good candidates, because 
pioglitazone seems to be relatively ineffective at reducing 
macrovascular events in these patients and also because 
pioglitazone may be associated with an increase in leg 
revascularizations in this patient group [69]. Finally, it 
should be emphasised that PROactive cannot provide any 
insights into the impact of pioglitazone on primary CV 
events, possibly because the exposure to treatment was too 
short. 
  Both TZDs carry warnings regarding their propensity to 
cause edema and heart failure and the need for appropriate 
management of these symptoms. In the European Union, 
TZDs are contraindicated in patients with cardiac failure or 
history of cardiac failure (New York Heart Association 
[NYHA] Stages I to IV), whereas in the US their use is only 
contraindicated in those with Stage III-IV heart failure. For 
both TZDs, a key factor is predicting those patients who are 
most likely to develop edema and signs of heart failure 
(although, as noted above, there may be no adverse 162 Current Cardiology Reviews, 2009, Vol. 5, No. 3 Erdmann et al. 
consequences associated with this, at least for pioglitazone). 
Rapid weight gain may be a sign of fluid retention and could 
indicate the potential to develop edema and signs of heart 
failure. Furthermore, diagnostic techniques, such as brain 
natriuretic peptide measurement, may help to identify those 
patients likely to develop heart failure with TZD treatment 
and could help to establish whether symptoms reflect heart 
failure or simply volume overload [18]. Edema from causes 
not related to heart failure should not preclude TZD use and 
may be readily amenable to diuretic therapy [18]. 
  Both the European Medicines Evaluation Agency 
(EMEA) and the FDA have concluded that the benefits of 
both TZDs continue to outweigh any possible detrimental 
effects [15,80]. However, in the US, the FDA has recently 
added a black box warning for myocardial ischemia to the 
rosiglitazone labelling. In Europe, the EMEA has added the 
contraindication of an acute coronary syndrome (unstable 
angina, ST segment elevation MI [STEMI] and non-STEMI) 
on the labelling for rosiglitazone-containing products [81]. 
No similar changes or recommendations have been made for 
pioglitazone and pioglitazone is indicated for use in patients 
who are receiving insulin. The recently updated American 
Diabetes Association (ADA)/European Association for the 
Study of Diabetes (EASD) consensus algorithm also 
highlights the potential of rosiglitazone to increase MI and of 
pioglitazone to decrease MI (Fig. 4) [2]. 
CONCLUSION — SHOULD CONFUSION REIGN IN 
THE WORLD OF TZDS? 
  The TZDs are drugs with complex mechanisms of action 
that have multiple biological effects with the potential to 
influence various clinical outcomes. Gene expression studies 
have highlighted the marked differential effects of individual 
TZDs on a whole range of genes, although the functional 
consequences of these differences and their relevance in 
terms of CV risk remain to be elucidated. Furthermore, 
clinical studies suggest that the metabolic profiles of 
individual TZDs only partially overlap, particularly with 
regards to important lipid parameters, such as HDL-C. Thus, 
there is a sound justification (albeit hypothetical) for 
predicting that individual TZDs might have differing effects 
on CV outcomes, despite their similar effects on glycemic 
control. 
  For pioglitazone, at least, we can be relatively certain that 
there is no net increase in the risk of overall macrovascular 
events (based on both PROactive and meta-analyses) and no 
adverse clinical consequences of developing signs of heart 
failure (based on PROactive). The main secondary outcome 
of PROactive and a meta-analysis of RCTs provide good 
evidence of a significant benefit regarding the composite of 
death, MI or stroke. These outcomes data are important 
when assessing the overall clinical profile of pioglitazone. 
Fig. (4). Algorithm for the metabolic management of type 2 diabetes mellitus [1,2]. (Reprinted with permission from Nathan DM, et al, 
Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement 
from the American Diabetes Association and the European Association for the Study of Diabetes, Diabetologia 2006; 49: 1711–1721,
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  Similar robust data for rosiglitazone are lacking. The 
signal for increased ischemic cardiac risk reported for 
rosiglitazone based on data from meta-analyses has brought 
several key issues to the forefront. Firstly, it has led 
clinicians to question whether there are sufficient data 
available to suggest that rosiglitazone (or many other 
diabetes agents) provides a net beneficial effect on important 
clinical outcomes. Secondly, the available studies suggest 
that any evidence of clinical benefit (or harm) with one TZD 
cannot be extrapolated to another, and there are plausible 
mechanistic reasons for important differences. Thirdly, it has 
re-emphasised that the ability of a drug to lower glucose may 
not be sufficient in itself to have a beneficial effect on 
macrovascular outcomes [82].  
  We conclude that the benefits with both TZDs continue 
to outweigh the risks. Based on currently available data, 
there is good evidence to suggest that pioglitazone is not 
associated with an increased risk of ischemic CV events and 
may in fact provide an overall CV benefit (and an overall 
clinical benefit). Although there are reports from meta-
analyses that there is a risk of MI with rosiglitazone, there 
are no outcomes data to support this suggestion. Thus, we 
believe that, for pioglitazone at least, there is no reason for 
patients or physicians to be alarmed when making judicious 
use of this agent in appropriate patients. It has been 
suggested very recently that pioglitazone represents a 
reasonable next option in patients with type 2 diabetes who 
have macrovascular disease (not complicated by heart failure 
or not limited to the leg) in whom adequate glycemic control 
is not being achieved with metformin alone [27].  
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